Latest Industry Insights
What Do Advances in Structural Proteomics Mean for Drug Development?
This article will cover innovations in structural proteomics, a new way to identify drug targets across the proteome, a new method to dissect drug–protein interactions and the future of structure-based drug design.
Automated Liquid Dispensing Supports Versatility in Biotech
Automated liquid handling methods are an attractive alternative to manual approaches, allowing labs to redirect important resources. At SLAS 2023, Technology Networks spoke with Thermo Fisher Scientific to discuss how automated liquid dispensing can support versatility in biotech.
Probing the Biomarker Landscape of Human Disease
To find out more about the importance of improving biomarker discovery and how next-generation mass spectrometry-based systems can help to fill the current gap in biomarker technologies, Technology Networks spoke with Dr. Mo Jain.
The UK Is Facing a Science and Tech Exodus
In this opinion piece, Liz Sparrow discusses the real risk of the UK losing its science and technology communities as they face a series of challenges that are threatening their growth.
Accelerating Efficient Drug Discovery With the Power of AI
To find out more about how generative artificial intelligence (AI) is helping to accelerate and advance drug discovery processes, we spoke to Dr. Alex Zhavoronkov, CEO of Insilico Medicine.
High-Precision T-Cell Testing: Driving Diagnostics Forward
To learn more about T-cell testing, the types of diseases it can help to diagnose and its value in clinical trials, we spoke to Phill Keefe, chief executive officer of PerkinElmer’s Oxford Immunotec division.
Streamlining Lead Identification
To learn more about the Pioneer Antibody Discovery Platform and its potential impact on drug discovery and development, we spoke to Dr. John Cardone.
The Case for RRx-001 as a Radiation Countermeasure
This article overviews the science behind the potential use of RRx-001as a “radiation buster” with anti-inflammatory and anti-free radical properties to prevent or reduce both GI-ARS and H-ARS.
New Approaches for Cancer Therapies: Targeting the DNA Damage Response
We speak with Dr. Niall Martin, CEO of Artios Pharma, to learn more about the development of drugs to target the DNA damage response pathway in cancer.
Combine Harvesting: The Advantages of a Reverse Merger
In this opinion piece, Francois Rieger discusses why reverse mergers are the way forward for advanced therapies.